Market Research Reports and Industry Reports

Hepatitis C Virus Infection

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS
Freedom from injecting Interferon (IFN), treating major HCV genotypes WW and betting on vaccines could bring a sea of change in the treatment of HCV infection in the future. This year the first IFN-free drug options for HCV Genotype 2/3- Gileads Sofosbuvir/RBV (GS-7977, PDUFA Dec. 8, 2013) is expected to be approved and launched! By 2015 launch of Gileads Sofosbuvir/Ledipasvir (PhIII) and AbbVie/ Enantas (ABT-450r/ABT-472/ABT-333) should remove the need of IFN for GT1 genotype HCV patients as well!

Tapping the Bigger Market- ROW: Gilead is moving well towards offering the best treatment options to a broader HCV pt population WW. . Genotype 1 is common in Australia, China, Taiwan and other countries in North Asia, while genotype 6 is found in Vietnam and other Southeast Asian countries. In India and Pakistan, genotype 3 is predominant, while genotype 4 is found in Middle Eastern countries such as Egypt, Saudi Arabia and Syria. A PAN genotype effective drug is what most companies are trying to sequester in their pipeline. This report comprehensively covers the current Standard of Care, its limitations and Future options for the treatment of HCV infection.
Table 1: KEY PRODUCTS IN PIPELINE: IFN-FREE COMBINATION
Table 2 :US & EU MARKET SHARE OF HCV DRUGS IN COMBINATION WITH IFN
Table 3:KEY PIPELINE PRODUCTS VACCINE
Table 4:DATA FROM IFN-FREE COMBINATIONS
Table 5: VIRAL RESPONSE IN GENOTYPE-1 PATIENTS IFN COMBINATIONS
Table 6 :KEY ABSTRACTS OF AASLD 13
KEY MILESTONES TO 2015

List Of Tables

Figure 1 : PTS NOT CANDIDATES FOR IFN-BASED THERAPIES
Figure 2A :SOFOSBUVIR PHIII STUDY DESIGN IN GT2/3 HCV PTS IFN FREE
Figure 2B:SOFOSBUVIR PHIII STUDY DESIGN IN GT 1,4,5,6 HCV PTS IN COMBINATION WITH IFN
Figure 3A:ION-1 SOFOSBUVIR/LEDIPASVIR PHASE 3 FDC STUDY
Figure 3B:ION-2 SOFOSBUVIR/LEDIPASVIR PHASE 3 FDC STUDY
Figure 3C:ION-3 SOFOSBUVIR/LEDIPASVIR PHASE 3 FDC STUDY
Figure: 4A :HCV GENOTYPES IN DIFFERENT PARTS OF THE WORLD
Figure: 4B :HCV PREVALENCE IN DIFFERENT PARTS OF THE WORLD
Figure 5: ABBVIEs IFN-FREE COMBINATIONS PHIII DESIGNS
Figure 6 :SIMEPREVIR IFN-FREE COMBINATIONS
Chart 1A :US & EU MARKET SHARE OF HCV DRUGS IN COMBINATION WITH IFN
Chart 1B :US & EU MARKET SHARE OF IFN-FREE COMBINATION HCV DRUGS
Figure 7 :HIV & HCV CO-INFECTION
Figure 8 :DIFFERENCE BETWEEN HIV & HCV

List Of Figures

Table 1: KEY PRODUCTS IN PIPELINE: IFN-FREE COMBINATION
Table 2 :US & EU MARKET SHARE OF HCV DRUGS IN COMBINATION WITH IFN
Table 3:KEY PIPELINE PRODUCTS VACCINE
Table 4:DATA FROM IFN-FREE COMBINATIONS
Table 5: VIRAL RESPONSE IN GENOTYPE-1 PATIENTS IFN COMBINATIONS
Table 6 :KEY ABSTRACTS OF AASLD 13
KEY MILESTONES TO 2015

Global Nonalcoholic Steatohepatitis (NASH) Sales Market Report 2017

In this report, the global Nonalcoholic Steatohepatitis (NASH) market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022,

USD 4000View Report

Hepatitis Diagnostic Testing Market: US, Europe, Japan

The report presents a detailed analysis of the Hepatitis diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the Hepatitis definition, epidemiology

USD 9500View Report

Hepatitis C - Pipeline Review, H2 2017

Hepatitis C - Pipeline Review, H2 2017 latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis C - Pipeline Review, H2 2017, provides an overview of the Hepatitis C (Infectious Disease)

USD 2000View Report

Hepatitis C [2016]: Bulletin #3

This edition presents key opinion leader (KOL) views on recent developments in the hepatitis C virus (HCV) infection market. Topics covered include: Medivir AB communicating an update on the results

USD 1045View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
Country Code.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 1000
  • Site Licence    USD 2000
  • Enterprisewide Licence    USD 3000
$ 1000

Reports Details

Published Date : Oct 2013
No. of Pages :33
Country :Global
Category :Healthcare
Publisher :MP Advisors
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube
paykasa bozdurma,paykasa bozdurma,astropay bozdurma,paykasa,paykasa,paykasa bozdurma,paykasa,astropay bozdurma,justin kart,bitcoin bozdurma,paykasa bozum,paykasa kart bozdurma,
beylikduzu escort,bahçeşehir escort,escort istanbul,istanbul escort,sex hikayeleri,pendik escort,
pedalebiellese.com,
istanbul escort bayan,besiktas escort,maltepe escort,kadikoy escort bayan,tekirdag escort bayan,findikzade escort,antalya escort bayan,ankara escort bayan,
Böcek İlaçlama,şehirler arası nakliyat,şehirler arası evden eve nakliyat,ofis taşıma,gebze evden eve nakliyat,kadıköy evden eve nakliyat,istanbul evden eve nakliyat,epoksi zemin,
ankara escort,ankara escort,ankara escort,
tipobet,
seo teknikleri wordpress ücretsiz tema istanbul sexs shop hacklink e sigara sexs shop